Brief: Ampio Reports Top-line Results from Study of Ampion in Adult Patients With Severe Osteoarthritis of Knee

Ampio Pharmaceuticals

15/09/2021 14:21

Sept 15 (Reuters) - Ampio Pharmaceuticals Inc  AMPE.A :
    * AMPIO PHARMACEUTICALS ANNOUNCES TOP-LINE RESULTS FROM
AP-013
PHASE III STUDY OF AMPION IN ADULT PATIENTS SUFFERING FROM
SEVERE OSTEOARTHRITIS OF THE KNEE (OAK)
    * AMPIO PHARMACEUTICALS - AMPION DEMONSTRATED STATISTICALLY
SIGNIFICANT REDUCTION IN PAIN AND IMPROVEMENT IN FUNCTION AT 12
WEEKS IN SEVERE OAK PATIENTS
    * AMPIO PHARMACEUTICALS - RESULTS REFLECT STRONG SAFETY
PROFILE
WITH NO TREATMENT RELATED SERIOUS, MATERIAL ADVERSE EVENTS
    * AMPIO PHARMACEUTICALS - CURRENT CASH RUNWAY OF ABOUT 12
MONTHS
EXPECTED TO PROVIDE SUFFICIENT NEAR-TERM LIQUIDITY, FLEXIBILITY
TO SUPPORT BUSINESS OPERATIONS
    * AMPIO PHARMACEUTICALS INC - PLANS TO MEET WITH FDA TO
DISCUSS
PHASE III RESULTS AND BIOLOGICS LICENSE APPLICATION

Source text for Eikon:  ID:nPn3pl8Bpa 
Further company coverage:  AMPE.A 

 ((Reuters.Briefs@thomsonreuters.com;))